Veracyte appoints general counsel

Mar 02, 2022
Annie McGuire spent 13 years at Amgen earlier in her career

Nasdaq-listed Veracyte has recruited Annie McGuire as senior vice president and general counsel. She reports to CEO Marc Stapley.

McGuire has moved to Veracyte from biotechnology company Rakuten Medical, where she was general counsel and corporate secretary. Before that, she was vice president for legal at MyoKardia, which focuses on serious cardiovascular disease, and led the team through the company’s $13 bn acquisition by Bristol Myers Squibb.

Annie McGuire, Veracyte

Before that, McGuire spent 13 years at Amgen in a number of legal and compliance leadership roles, including senior corporate counsel for global commercial operations and employment and executive compensation. She began her legal career at Proskauer Rose in New York.

According to an SEC filing, James Erlinger, who was executive vice president, general counsel and secretary of Veracyte, retired from the company with effect from July 31, 2021.

Veracyte is a diagnostics company that aims to help patient care through answering clinical questions that inform diagnosis and treatment decisions.

Stapley says in a statement: ‘We are delighted to welcome Annie to Veracyte. She brings with her significant experience in Fortune 100 and other healthcare companies. Her proven leadership in running global legal operations and serving as a strategic business partner within large and growing companies will be critical to Veracyte’s success as we continue advancing our strategic vision.’

Sign up to get stories direct to your inbox
Stay informed on the latest trends and developments in the fast-moving world of corporate governance by signing up for our popular newsletters. Our weekly and monthly updates will provide you with expert analysis, timely updates and comprehensive coverage of regulatory updates, governance trends and best practices, careers and much more.
Cs logo Cs logo